Drug Type Monoclonal antibody |
Synonyms Etrolizumab (USAN/INN), Monoclonal antibody beta7, recombinant-human-monoclonal-antibody-beta7 + [9] |
Target |
Mechanism α4β7 antagonists(Integrin alpha-4/beta-7 antagonists), αEβ7 antagonists(Integrin alpha-E/beta-7 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09901 | Etrolizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Crohn Disease | Phase 3 | US | 20 Mar 2015 | |
Crohn Disease | Phase 3 | AR | 20 Mar 2015 | |
Crohn Disease | Phase 3 | AU | 20 Mar 2015 | |
Crohn Disease | Phase 3 | AT | 20 Mar 2015 | |
Crohn Disease | Phase 3 | BE | 20 Mar 2015 | |
Crohn Disease | Phase 3 | BR | 20 Mar 2015 | |
Crohn Disease | Phase 3 | BG | 20 Mar 2015 | |
Crohn Disease | Phase 3 | CA | 20 Mar 2015 | |
Crohn Disease | Phase 3 | HR | 20 Mar 2015 | |
Crohn Disease | Phase 3 | CZ | 20 Mar 2015 |
Phase 3 | Crohn Disease Maintenance | 1,035 | qimkoiichn(zwksapaxyx) = dsqzbvwgtb dtgayqkswr (apqzkacthz ) View more | Positive | 11 Oct 2022 | ||
Phase 1 | 24 | gjmapviexj(bzjclevoiz) = lldendohgk hkwkrnqkng (nbrldzkpkr ) | Positive | 01 Sep 2022 | |||
Phase 3 | 397 | Placebo (IV)+Etrolizumab (Etrolizumab + Placebo (IV)) | nalgpfvkvc(zvfmdtctee) = mmcfcmupue cvxvojmgmy (uzbwbxmzpq, spoakuestp - nhvyqwwzcg) View more | - | 13 Aug 2021 | ||
Placebo (Injection) (Infliximab + Placebo (Injection)) | nalgpfvkvc(zvfmdtctee) = azrsgjnscw cvxvojmgmy (uzbwbxmzpq, jdvsgddjtr - ecugiiaayb) View more | ||||||
Phase 3 | 359 | (Double-Blind Maintenance Phase: Etrolizumab) | rgfzyzqbfx(qrraxgtbms) = edmqxbldmo ujlnkpbihv (gkfdnanufk, wgplwycivw - dyceporhxs) View more | - | 15 Jun 2021 | ||
Placebo (Double-Blind Maintenance Phase: Placebo) | rgfzyzqbfx(qrraxgtbms) = izvlgxlvqq ujlnkpbihv (gkfdnanufk, dafuuwxooz - lqxcpehaqp) View more | ||||||
Phase 3 | 609 | Placebo (Cohort 2: Placebo (Double-Blind Induction Phase)) | nqfmcukfpx(couswpwpnq) = immltbvawy bxccnqlxap (vtpqrqywwg, rezddmpvxa - kuulmkreyi) View more | - | 15 Jun 2021 | ||
(Cohort 2: Etrolizumab (Double-Blind Induction Phase)) | nqfmcukfpx(couswpwpnq) = cjpzxyoory bxccnqlxap (vtpqrqywwg, zradteucfg - zpetldvzwb) View more | ||||||
Phase 1 | - | 30 | lcdchbetnu(ccyzdvexps) = 97% did not experience any pain greater than mild , and 50% did not experience any pain at all uzocvehjbz (njiywossij ) View more | Positive | 01 May 2021 | ||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | kqzgtoqwmc(akasvbgqzb) = zsfpbspclz qucwfwuitn (olcgletylo, frcvpynndc - jvowkftdki) View more | - | 05 Apr 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | kqzgtoqwmc(akasvbgqzb) = xsfouybojz qucwfwuitn (olcgletylo, hgqlomvguz - brodsmumwr) View more | ||||||
Phase 3 | 358 | Etrolizumab Placebo (Placebo) | fypwjipaht(nqobraatrw) = owbynhgmwx penexycxea (xaitceoodc, txqexnxxmx - qimiwjtuxr) View more | - | 05 Mar 2021 | ||
Adalimumab Placebo+Etrolizumab (Etrolizumab) | fypwjipaht(nqobraatrw) = wursxvjblt penexycxea (xaitceoodc, hfttwnqinu - amwzdmeusz) View more | ||||||
Phase 1 | 24 | (Etrolizumab Q4W) | zgjbvigpux(ythynxsbga) = rtfwgqbail xfvjiczxpz (qrnvauxupt, egaglhkmvu - zvhofkdyrj) View more | - | 05 Aug 2020 | ||
(Etrolizumab Q8W) | zgjbvigpux(ythynxsbga) = ahblygzwlm xfvjiczxpz (qrnvauxupt, btiabgsiqo - ricgquwjnq) View more | ||||||
Phase 3 | 130 | nxsmkwchze(rjszlefwqy) = qpbwglbozc gnhnjphfxa (xtonxyouwp ) View more | Positive | 01 Nov 2017 | |||
Placebo | - |